Gossamer Bio (GOSS) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Gossamer Bio (GOSS) over the past year, losing 30.8% versus a loss of 95.6%. Zhengye Biotechnology is the larger company by market cap ($70.1 million vs $65.6 million), about 1.1 times the size. Zhengye Biotechnology converts more of its revenue into profit, with a net margin of -60.0% versus -351.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOSS | ZYBT |
|---|---|---|
| Share price | $10.72 | $1.48 |
| Market cap | $65.57M | $70.14M |
| 1-day change | -4.54% | -2.63% |
| YTD return | -95.68% | +28.70% |
| 1-year return | -95.62% | -30.84% |
| 5-year return | -98.74% | — |
| EPS (TTM) | $-42.41 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $48.47M | $16.64M |
| Revenue growth (YoY) | -57.74% | -34.83% |
| Net income (latest FY) | $-170.37M | $-9.98M |
| Gross margin | — | 20.51% |
| Operating margin | -352.23% | -60.60% |
| Net margin | -351.49% | -59.99% |
| 52-week high | $309.60 | $8.01 |
| 52-week low | $8.29 | $0.616 |
| Distance from 52-week high | -96.54% | -81.52% |
| Analyst consensus | buy | — |
| Avg. price target upside | +669.40% | — |
| Average volume | 243.40K | 569.22K |
| Shares outstanding | 6.12M | 47.39M |
| Employees | 161 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYBT has outperformed GOSS by 64.8 percentage points over the past year.
- Zhengye Biotechnology is more profitable, keeping -60.0 cents of every revenue dollar as net income versus -351.5 cents for Gossamer Bio.
- Zhengye Biotechnology grew revenue faster in its latest fiscal year (-34.83% vs -57.74%).
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
GOSS vs ZYBT FAQ
Which is bigger, Gossamer Bio or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $70.14M compared with $65.57M for Gossamer Bio (GOSS).
Which stock has performed better over the past year, GOSS or ZYBT?
ZYBT returned -30.84% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Gossamer Bio and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.